非B细胞来源IgG（non B-IgG）是一类不同于经典B细胞来源IgG的新分子，其在肿瘤中的高表达及促进肿瘤发生发展的作用日益引起人们关注。我们前期研究发现，non B-IgG在肾透明细胞癌组织及细胞系中高表达，并且对肾癌的恶性生物学行为具有促进作用，但目前对其促进肿瘤发生发展的具体作用机理并不清楚。本项目拟通过构建non B-IgG稳定上调及下调的肾癌细胞株，采用高通量测序及蛋白组学技术分析non B-IgG所调控的信号转导途径，筛选出其发挥功能的信号通路并在细胞、基因和蛋白水平对上述通路进行验证，揭示其促进肾癌进展的分子机制。同时研究non B-IgG对肾癌靶向治疗的影响以及其特异性抗体（RP215）治疗肾癌的价值。该研究不仅有助于阐明non B-IgG促进肾癌发生发展的分子机制，而且能为肾癌的靶向治疗、免疫治疗和预后判断提供新的参考，具有重要的临床意义。

Non B cell-derived IgG (non B-IgG) is a new protein, which is different from the classical B cell-derived IgG. The high expression of non B-IgG in tumor and its role in facilitating tumor progression are gaining increasing interest. Our previous studies found that non B-IgG existed the phenomenon of high expression in renal cell carcinoma (RCC) tissues and cell lines and correlated with aggressive biological behaviors of RCC. However, the molecular mechanism of non B-IgG in RCC is not clear yet. The project intends to analyse the changes of signaling pathways in non B-IgG over-expressed and low-expressed renal carcinoma cell lines via High-Throughput Sequencing and Proteomic technique to screen out the related signaling pathways of non B-IgG in RCC and verify the role of non B-IgG promoting tumor progression in cells, gene and protein level, revealing the molecular mechanism. At the same time , to confirm the value of non B-IgG on renal cancer targeted therapy and the effect of specific antibody—RP215 in the treatment of RCC. This study not only helps to elucidate the molecular mechanism of non B-IgG facilitating RCC progression, but also provides a new reference for the targeted therapy, immune therapy and prognosis of RCC.